


A large, faint, light blue watermark of a caduceus (a staff with two snakes entwined and wings at the top) is centered in the background of the page.

QUANTUM MEDICINAL RESEARCH AND DEVELOPMENT COMPANY LIMITED

ENVIRONMENTAL
POLICIES AND PROCEDURES




TABLE OF CONTENTS

1. Environmental Policy	-----Page 3
-------------------------	-------------

ENVIRONMENTAL POLICY

Introduction:

The Quantum Medicinal Charter: Transforming Our World.

1. Quantum Medicinal Research and Development Company Limited is fully committed to the 2030 Sustainable Development Goals (SDGs) of the United Nations, as outlined in the Resolution adopted at the United Nations General Assembly Seventieth Session, Agenda items fifteen (15) and One Hundred and Sixteen (116) on the 25th of September 2015. We are aware that our actions can have a significant impact on achieving these goals.
2. Quantum Medicinal Research and Development Company Limited is an analytical think tank of professionals. We are skilled in Health-related engineering and technology, operations management, facilities systems, and procurement processes. We work in conjunction with our sister company, ESPY Technical Services Limited, which has sourced equipment, parts, and services products for hospitals in Trinidad.
3. Quantum Medicinal provides comprehensive Healthcare solutions to our local and regional medical sectors to implement SDG 3 Good Health and Well-being. Our mission is to foster the continuous development of leaders and organisations within the medical industry, while actively pursuing strategically sustainable engineering solutions that benefit humanity.
4. Research and development with a clear focus on complete patient healthcare needs, our company shall promote and foster the latest technological advancement(s) that serve our customers within the Americas. Our core objectives are as follows:
 - i. To provide healthcare Technology management and clinical Engineering solutions to the Caribbean.
 - ii. The provision of medical device services and sales for the Caribbean through our affiliates and manufacturers.

- iii. To be the market leader in the development, sales, and services of Medical 3D printing for the Caribbean.

Partnership for the Goals

5. Quantum Medicinal Research and Development Company Limited is committed to the United Nations Global Compact and the Sustainable Development Goals. We have partnered with The Quantum Foundation (TQF), a non-governmental, non-profit company registered in Trinidad and Tobago that shares our commitment and promotes these global initiatives.
6. TQF has taken up the challenge put forward by Mr. Kofi Annan, seventh Secretary-General of the United Nations, to ensure that sustainable development becomes a reality for everyone worldwide. We are committed to implementing this framework to drive economic growth, promote social justice, and encourage environmental stewardship. The Quantum Medicinal Charter has expressly adopted the Sustainable Development Goal (SDG) 3 targets, “Ensure healthy lives and promote well-being for all at all ages,” in executing its mandate.
7. Quantum Medicinal Research and Development Company Limited intends that all workers be employed by TQF and reassigned to the specific company to promote the efficiency of our operations, as well as Goal 17, Partnership for the Goals. Quantum Medicinal Research and Development Company Limited is currently undergoing a restructuring process wherein all employees will be hired directly under TQF and reassigned to Quantum Medicinal Research and Development Company as part of our bespoke business model to promote NGO capacity building, the Sustainable Development Goals, and the United Nations Global Agenda.
8. The Global Compact speaks to private sector partnership and commitment to the international standard set by the 2030 Agenda. This is our attempt to ensure its accelerated implementation, particularly within the Latin American and Caribbean (LAC) Region. TQF provides capacity building and business process outsourcing services to ensure that our internal policies and guidelines comply as far as possible with international standards regarding labour rights, anti-corruption, environmental sustainability, and human rights.

9. We have adopted TQF's policy documents and commit to engaging TQF as our partner to monitor and evaluate our compliance with the standards above and recommend relevant methods of implementation in the future. Currently, TQF provides capacity building and business process outsourcing services for various companies. All contracts stemming from TQF are preloaded with a commitment to the UNGC as part of their terms of reference.
10. Quantum Medicinal Research and Development Company Limited aims to partner with the World Health Organisation to secure the accelerated implementation of SDG 3: Good Health and Well-Being.
11. Quantum Medicinal Research and Development Company Limited firmly believes that safeguarding the environment is a collective responsibility. We are committed to effecting positive change through all facets of our operations. By integrating sustainability into Quantum Medicinal Research and Development Company Limited's core functions, we strive to contribute meaningfully to a healthier planet and a more sustainable future for all.

Applicability:

12. This policy applies to all departments and teams at Quantum Medicinal Research and Development Company Limited that are involved in planning, executing, and evaluating actions and projects.
13. At Quantum Medicinal Research and Development Company Limited, our commitment to Environmental Policy underscores our dedication to achieving excellence in all facets of our operations. We understand that efficient action implementation and thorough evaluation are crucial to attaining our strategic goals and maintaining high standards of performance and accountability.

Purpose:

14. This policy clearly defines our commitment to environmental stewardship and delineates the fundamental principles and procedures governing our global operations. It applies to all personnel, contractors, and affiliated parties involved in our activities.

Environmental Objectives:

15. Quantum Medicinal Research and Development Company Limited is steadfastly dedicated to environmental conservation. Acknowledging the substantial impact of our operations on the planet, we are firmly committed to mitigating this impact through conscientious practices and pioneering solutions. Furthermore, we recognise and align with the United Nations mandate in implementing the [Global Compact Environment Principles](#) within our organisational framework:

- i. [Principle 7](#): *Businesses should support a precautionary approach to environmental challenges;*
- ii. [Principle 8](#): *undertake initiatives to promote greater environmental responsibility and*
- iii. [Principle 9](#): *encourage the development and diffusion of environmentally friendly technologies.*

16. Quantum Medicinal Research and Development Company Limited is committed to collaborating in the prevention/ mitigation of the risks and impacts of Climate Change. We have adopted the following commitments:

- i. Promoting Environmental Sustainability through Enhanced Energy and Resource Management.
- ii. Emphasizing sustainability, efficiency, and continual improvement in our procurement practices.
- iii. Mitigating our carbon footprint by deploying energy-conserving technologies and optimising resource allocation.
- iv. Prioritizing waste reduction and recycling efforts.
- v. Implementing strategies for waste reduction while advocating for recycling and material reuse.

- vi. Ensuring adherence to relevant environmental laws and regulations.
- vii. Constantly refining our environmental protocols and performance standards.
- viii. Collaborating with stakeholders to champion environmental stewardship.
- ix. Ensuring alignment of our internal policies and procedures with international and ISO standards.
- x. Engaging with our suppliers and partners to uphold shared values and best practices in environmental management.
- xi. Investing in employee training and development to cultivate environmental awareness and encourage proactive involvement in our sustainability initiatives.
- xii. Managing waste and by-products in compliance with both international and local regulations.
- xiii. Practicing sustainable procurement insofar as possible.
- xiv. Striving for a zero-carbon footprint throughout our activities.
- xv. Support the development and diffusion of environmentally friendly technologies.
- xvi. Participate in bi-annual activities geared towards ecosystem restoration and protection.
- xvii. Uphold its obligations under domestic legislation and international custom to safeguard against environmental degradation, including strict adherence to **the Environmental Management Act Chapter 35:05** of Trinidad and Tobago.
- xviii. Identifying and implementing best practices based on evaluation results and industry standards regarding collective action on environmental management, carbon reduction policies, and waste management.
- xix. Offering training and support to team members to enhance their skills and knowledge related to action implementation and evaluation of climate change.

Implementation:

17. Quantum Medicinal has established a cross-functional committee to address our commitment to the UNGC and our corporate responsibility to environmental protection. We have partnered with The Quantum Foundation to act as an external

auditor assessing our compliance with company policy catered to the Principles of the Global Compact.

The Cross-Functional Committee on Environment, Principles 7, 8 and 9 of the UNGC.

18. Quantum Medicinal Research and Development Company is a small to medium enterprise. Noting this reality and its effect on our organisational structure, we have taken additional steps to engage with and implement the Global Compact Environment Principles purposefully. One of these steps is implementing a Cross-Functional Committee on Environmental Sustainability.
19. The Committee shall comprise a representative of Senior Management (CEO or someone with delegated authority), a representative of TQF who has been engaged as our partner overseeing our implementation of and compliance with internal policy and international best practices, and a selected staff representative who shall be responsible for communicating the committee's recommendations to staff and stakeholders.
20. Role and Function of the Cross-Functional Committee Members:
 - i. Representative of Senior Management—Understand and approve the recommendations of TQF and ensure their implementation into company policy. Where divergent opinions occur, senior management ensures that said discrepancies are resolved and that the company can move forward with settled views on challenging issues. Senior management must identify priority areas for risk assessment activities and ensure that due diligence is performed at all times to identify and prevent or at least mitigate any potential negative impact on sustainability.
 - ii. TQF- assesses the company's existing policies and ensures compliance. These policies must then be assessed against international best practices so that there is a constant process of monitoring and evaluation in the future so that progress is never stagnated. TQF must then communicate its findings by reporting to senior management and frequently liaising with that arm of the committee to ensure that the partnership achieves its aim of promoting compliance with the UNGC. TQF must then recommend progressive action to ensure that the company direction aligns with the Ten Principles and evaluate the implementation of its recommendations annually. TQF shall also be responsible

for conducting training sessions on company policies to assist with communicating and understanding company policy.

- iii. Staff Representative- is responsible for communicating the decisions of the Committee to staff and stakeholders. While not responsible for compliance, this role is essential to ensuring that the relevant policies are accurately communicated company-wide and understood. Should further questions or challenges arise, the staff representative must refer persons to TQF or directly to senior management to address any concerns effectively and efficiently. A code of confidentiality covers all referrals, and all staff and stakeholders must be assured that no adverse reaction will emanate from any action related to this policy.

Risk Assessment and Due Diligence

21. A clear and structured process guides Quantum Medicinal Research and Development Company Limited's approach to risk assessment and due diligence reporting per this policy guideline.

Risk Assessment Guidance:

22. Identifying the Risk:

Promoting environmental sustainability practices in a business dynamic must begin with sufficient knowledge and training for staff. Therefore, our risk assessment guidance starts with ensuring that staff is periodically trained in this area by in-house experts on sustainable development. Our external partner, The Quantum Foundation, has approved our training programme, and the training has been implemented in partnership with TQF. The following thematic areas have been identified:

- i. Legal risks
 - ii. Commercial and operational risks
 - iii. Reputational risks
23. Quantum Medicinal Research and Development Company Limited is also committed to engaging third-party auditors to examine the company's sustainability practices and to assist in forecasting and preparing budgetary documents for the following financial year. This mechanism provides another layer of risk assessment via a third-party

partner, ensuring an independent evaluation of the Company across all material levels, yielding a robust risk assessment process.

Mitigating the Risk:

24. Due to our size, we have implemented several initiatives to ensure sufficient oversight of company activities:

- i. Monitoring serves as a fundamental element of our implementation strategy. Quantum Medicinal Research and Development Company Limited utilises established performance metrics and conducts regular reviews to track progress, allowing us to address any challenges and maintain project momentum effectively. This continuous oversight ensures that our actions align with our objectives and that any deviations are promptly addressed. Our company is young and still streamlining our activities, having introduced our policy commitments on the Global Compact. The next step is monitoring our policy objectives while assessing this against international best practices.
- ii. There is increased managerial oversight when engaging new partners or third parties, coupled with tailored training for senior management in decision-making positions to continuously update their ability to identify, mitigate, and prevent risks attached to environmental principles. We also require increased due diligence mechanisms when engaging suppliers or making significant investments. We review these internal mechanisms periodically through our partnership with TQF to ensure that our risk strategy to minimise our overall risk exposure can stand the test of the international system. Before a third party is engaged, the following is considered:
 - a. Legal status and type of organisation, as well as the jurisdiction of incorporation.
 - b. Assessment of ownership structure, including financial management and affiliated entities.
 - c. Determination of any actual or potential conflict of interest.
 - d. Business reputation of intended partner.


- e. Business partner's internal sustainability programme
 - f. Business partner's willingness to abide by our environmental policy and commitment to the United Nations Global Compact.
 - g. Business partners programme for sustainable procurement.
- iii. Evaluation constitutes an essential component of our unwavering dedication to continual enhancement. Quantum Medicinal Research and Development Company Limited meticulously evaluates the abovementioned against predetermined objectives and key performance indicators, as the United Nations Guiding Principles on Business and Human Rights suggests. In this regard, environmental and social impact assessments of our projects are essential. This data-centric approach empowers us to make well-informed decisions and refine our strategies to achieve even more superior outcomes in the future.
- iv. Transparency and accountability are fundamental principles of Quantum Medicinal Research and Development Company Limited's policy. The Company is dedicated to providing our stakeholders with regular progress reports and comprehensive final evaluation reports. This ensures all parties know our achievements, obstacles, and upcoming initiatives. Embracing this practice of openness fosters trust and nurtures a culture of shared responsibility and accountability. All business partners, employees and associated third parties are also informed of our commitment to the United Nations Global Compact.
- v. Due diligence is centred on our responsibility to cater to and protect human rights. At the same time, we continuously fight to address any identifiable risk associated with our business portfolio that can hamper or constrain the promotion of human rights. As a Small to Medium Enterprise, we commit to the following:
- a. Cultivate a business culture that promotes focus on environmental action and sustainability, recognising the significant impact that Climate Change is forecasted to have on our Region. Communication is vital, and senior management has

acknowledged the power of dialogue to spread acceptance of this type of company culture. Any potential conflicts must be identified as soon as practicable and resolved accordingly.

- b. Focus on an action-oriented approach: Senior management has already partnered with TQF to ensure a pragmatic approach to training and development for its staff related to the implementation of company policy, bringing it to life at the most crucial resource level—human resources.
- c. Collaboration is critical: We encourage cross-sectorial dialogue towards progress. We applaud our staff, who can transfer knowledge across different working groups, corporate entities, and cultures to facilitate the dissemination of critical information regarding the UNGC initiative. In this regard, inter- and intra-company dialogue is encouraged.
- d. Building Trust: no company can progress independently in this globalised era. We encourage our staff to build long-term relationships with trusted partners with whom a relationship can be established. Doing business with like-minded corporate entities will ensure that the UNGC principles are disseminated effectively and that all parties understand and accept our internal standards as they relate to environmental protection. This will eventually allow SMEs to reach a place where there is corporate will to engage on systemic issues challenging progress on critical obstacles to promoting and protecting environmental rights as human rights.
- e. Freedom to forge pathways to higher standards—while we never want to reinvent the wheel, we understand the importance of unlimited design. The potential for success is exponential, and harnessing growth is critical to revitalising the industry. When business takes a stand for human rights, it is noticed. Implementing inter-company policy via continuous engagement,

monitoring, and evaluation at all levels of company governance is essential to its success.

25. Quantum Medicinal Research and Development Company Limited has focused on implementing the UN Climate Change Model in the Adaptation Process into its corporate business model. The overlapping areas of planning and design are transferrable to the corporate model, and the adaptation life cycle is depicted below as a reference:



Source: [Introduction | UNFCCC](#)

26. This model highlights the public-private partnership required to effect a sustainable environmental policy and the ingredients needed for an implementable corporate strategy that addresses the issue of climate sustainability. Quantum Medicinal Research and Development Company Limited, therefore, commits to engaging in the following activities:

- i. Providing a think-tank to generate discussion on climate change adaptation mechanisms within the private sector;
- ii. Strengthening internal technical and institutional capacity to monitor our environmental impact;

- iii. Raising awareness and ambition by insisting on our partner's conformity with our environmental policy, particularly regarding engaging third parties that practice sustainable procurement.

Policy Review:

- 27. This policy will be reviewed annually or as needed to ensure its continued relevance and effectiveness. Updates and revisions will be made as necessary to address emerging environmental issues and advancements in sustainability practices.

Approval and Implementation:

- 28. This policy has been approved by Criston J. Williams, CEO of Quantum Medicinal Research and Development Company Limited and is effective as of August 2024. All employees are expected to adhere to the principles and practices outlined in this policy.

Signed,



Recoverable Signature

X Criston J Williams

Criston J Williams

Director-Quantum Medicinal Research & Dev.

Signed by: 7f272d91-257f-4f17-a29b-0b39491b76ae



Bibliography

1. United Nations Global Compact, Guide to Corporate Sustainability. United Nations Global Compact, New York: 2014. [publications/UN_Global_Compact_Guide_to_Corporate_Sustainability.pdf](https://publications/un-global-compact-guide-to-corporate-sustainability.pdf) (d306pr3pise04h.cloudfront.net)
2. United Nations Office of the High Commissioner for Human Rights, Guiding Principles on Business and Human Rights: Implementing the United Nations “Protect, Respect and Remedy” Framework. United Nations, Geneva: 2011. [guidingprinciplesbusinesshr_en.pdf](https://www.ohchr.org/documents/e/hqhr/wp-content/uploads/201106/guidingprinciplesbusinesshr_en.pdf) ([ohchr.org](https://www.ohchr.org))
3. United Nations, “Agenda 21,” United Nations Conference on Environment and Development, Rio de Janeiro, Brazil, 3 to 14 June 1992. [Agenda21.doc](https://www.un.org/Depts/da/agenda21/agenda21.doc) ([un.org](https://www.un.org))
4. United Nations Global Compact, Local Network Resources Engagement Framework, “Caring for Climate”, [Caring for Climate | UN Global Compact](https://www.unglobalcompact.org/About-UNG/Initiatives/Local-Network/Local-Network-Resources-Engagement-Framework)
5. United Nations Climate Change, “Adaptation and Resilience”, [Introduction | UNFCCC](https://unfccc.int/adaptation-and-resilience)
6. United Nations Environment Programme, Adaptation Gap Report 2021, Nairobi: 2021. [AGR21.pdf](https://www.unep.org/adaptation-gap-report)